- Home
- / Pharmocann
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pharmocann financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₪0
2023-09-14
Market Capitalization
₪277.5 M
2023-09-14
CreditSafe Score
?
Score changed on Jun 05, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3M | 20.9M | 27.9M | 29.0M | 22.7M | 14.4M | ||
| Cost of goods sold | 1.1M | 9.8M | 12.0M | 21.6M | 26.1M | 15.6M | ||
| Gross profit | 156.0K | 11.1M | 15.9M | 7.4M | (3.4M) | (1.1M) | ||
| Gross profit margin, % | 12.3% | 53.1% | 56.9% | 25.5% | -15.0% | -7.3% | ||
| Operating expense total | 180.0K | 58.5M | 13.7M | 15.1M | 13.0M | 7.8M | 2.5M | 1.9M |
| Depreciation and amortization | 919.0K | 843.0K | 1.8M | 3.9M | 666.0K | |||
| EBITDA | (24.0K) | (47.4M) | 2.1M | (7.7M) | (16.4M) | (8.8M) | (2.5M) | (1.9M) |
| EBITDA margin, % | -1.9% | -227.0% | 7.7% | -26.6% | -72.5% | -61.2% | ||
| EBIT | (24.0K) | (48.3M) | 1.3M | (9.5M) | (22.1M) | (9.6M) | (2.5M) | (1.9M) |
| EBIT margin, % | -1.9% | -231.5% | 4.7% | -32.7% | -97.6% | -66.7% | ||
| Interest income | 63.0K | 26.0K | 24.0K | 209.0K | 2.0K | 3.0K | ||
| Interest expense | 1.0K | 216.0K | 162.0K | 260.0K | 237.0K | 132.0K | 2.0K | 17.0K |
| Pre tax profit | 27.0K | (44.5M) | 6.1M | (22.4M) | (24.5M) | (9.7M) | (2.5M) | (1.9M) |
| Income tax expense | 2.0M | 2.4M | (3.0M) | 773.0K | ||||
| Net Income | 27.0K | (46.5M) | 3.6M | (19.3M) | (25.3M) | (9.7M) | (2.5M) | (1.9M) |